 The protein levels of NDRG2 in the hippocampus of AD mice were increased with the development of AD.
Introduction
As a neurodegenerative disease that can lead to many deficiencies in memory, executive ability, visual space, language communication, abstract thinking, learning and calculation, Alzheimer's disease (AD) is one of the primary diseases causing disability and death worldwide [1, 2] . AD is characterized by the extracellular senile plaques formed by aggregation of amyloid β and the intracellular neurofibrillary tangles formed by aberrant accumulation of tau protein [3] , resulting in the primary degeneration and necrosis of neurons [4] . However, no effective treatment exists for AD, and a high failure rate in the clinical phase of new drug development has occurred in recent years [5] . Therefore, the identification of new key molecules and mechanisms underlying AD is urgently needed.
Human N-myc downstream-regulated gene 2 (NDRG2) is located on chromosome 14q11.2 and contains 16 exons and 15 introns [6] . It encodes a protein with 371 amino acid residues and has a molecular weight of approximately 41 kDa [7] . NDRG2 is reported to be highly expressed in terminally differentiated tissues such as the brain [8] , heart [9] , muscle [10] and salivary glands [11] . NDRG2 is mainly distributed in the outer cortex, choroid plexus and epithelium of fetal mice [12] . Moreover, NDRG2 is distributed throughout the whole brain and is mainly expressed in astrocytes of adult mice [12] . The mRNA and protein levels of NDRG2 in the brain tissues from AD patients were significantly higher than those from the control elderly people [13] .
NDRG2 was colocalized with plaques and neurofibrillary tangles in the brains of a J o u r n a l P r e -p r o o f mouse model of AD [14, 15] . Here, we also found a gradual increase in the expression of NDRG2 in the mouse hippocampus with the pathological progression of AD.
Based on these studies, we proposed the hypothesis that during the pathological development process of AD, the accumulated amyloid β, as a kind of cell stress, induces the upregulation of NDRG2.
To test this hypothesis, we generated two independent AD mouse models lacking NDRG2 expression and analyzed the memory ability in these models. We provide evidence that strongly suggests that NDRG2 is an endogenous neuroprotectant in the development of AD.
Materials and methods

Animals
APP/PS1 double-transgenic [B6.Cg-Tg(APPswe,PSEN1ΔE9)85Dbo/Mmjax] mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All APP/PS1 mice used in this study were hemizygous. All C57BL/6 mice were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The
Ndrg2-knockout (Ndrg2
-/-behavioral phenotyping were blinded to the mouse genotyping and grouping.
Immunofluorescence
Mice were anesthetized with a mixture of chloral hydrate (3 mg/10 g of body weight), perfused with 0.01 M phosphate-buffered saline (PBS), fixed with 4% cold paraformaldehyde phosphate buffer (PFA, pH 7.4) and dehydrated with 30% sucrose solution. The brains were quickly extracted and frozen in OCT (optimal cutting temperature) Compound (Fisher Scientific). Briefly, blocks were stored at -20°C for 30 min before slicing on a cryostat at a 16 μm thickness. Slices were postfixed for 20 min in ice-cold 4% PFA before a quick wash with 0.01 M PBS. Sections were then incubated for 2 h in 5% normal donkey serum (NDS) in 0.01 M PBS before overnight incubation with primary antibodies (rabbit anti-NDRG2, 1:100, Abcam, ab174850; mouse anti-glial fibrillary acidic protein (GFAP), 1:300, Cell Signaling, #3670) in 1% NDS and 0.01 M PBS. After three washes in PBS for 10 min each, sections were incubated with anti-rabbit-594 and anti-mouse-488 secondary antibodies for 2 h (1:400, Life Technologies, # R37117, # A-10680, respectively), washed again three times with PBS and stained with 4,6-diamidino-2-phenylindole (DAPI) to visualize the nuclei. Slices were mounted and cover-slipped with mountant (Invitrogen). The brain slices were observed under a confocal microscope with appropriate laser scanning and filters for Alexa 488 and Alexa 594.
Immunoblotting
Brain samples were collected and homogenized in RIPA lysis buffer containing J o u r n a l P r e -p r o o f phosphatase and protease inhibitor cocktails (Roche). For protein extraction, the samples were centrifuged at 12,000 rpm for 15 min at 4°C. The supernatant was removed to a new tube. Protein levels were assessed with a Bradford assay with BSA as the standard. Equal amounts of protein samples were separated by SDS-PAGE 
Novel object recognition test
The open field apparatus was constructed of a box measuring 40 cm × 40 cm × 35 cm.
In the novel test situation, each animal was placed in the bottom right corner of the test apparatus and videotaped for 5 min using a video camera located 100 cm away from the arena. During each interval between the phases of experiments, the arena was cleaned with cotton soaked in 70% alcohol. The experimenters conducting the genotyping were blinded to the identities of the mice. The first day, the following behaviors were recorded for each mouse: the number of lines crossed by the mouse J o u r n a l P r e -p r o o f min. All videotapes were analyzed by an experimenter. Novel object preference was calculated as follows: percentage = time spent exploring the novel object / (time spent exploring the novel object + time spent exploring the familiar object). Object exploration was defined as each instance in which a mouse's nose touched the object or was oriented toward the object and came within 2 cm of it. Chewing the object or climbing onto the object did not qualify as exploration.
Stereotaxic surgery
All surgeries were performed under aseptic conditions using isoflurane (1.4%) as the anesthetic. The skull surface was exposed, and 30-gauge syringe needles were used to infuse 0.5 μL of Aβ oligomers or saline into the left lateral ventricle at a rate of 0.1 μL/min. The coordinates of the stereotaxic apparatus were as follows: 0.22 mm posterior to the bregma, 1.0 mm to the left of the midline and 1.4 mm in depth. All J o u r n a l P r e -p r o o f mice were allowed to recover for 2 weeks.
RT-PCR analysis
Mouse brain samples were collected and homogenized in TRIzol reagent (Life Technologies), and total RNA was extracted according to the manufacturer's protocol.
Then, the RNA samples were quantified using an ultraviolet spectrophotometer at 260 nm. Equal amounts of RNA were reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Target cDNA levels were determined by RT-PCR (Thermo Fisher, Wilmington, USA) using SYBR Green 
Statistical analysis
The data are represented as the mean ± SEM. Statistical significance was evaluated using Student's t test analysis or one-way ANOVA followed by the Tukey-Kramer post hoc test (GraphPad Prism 7.0 software). P < 0.05 was used to determine significance where indicated.
Results
The expression levels of NDRG2 increased with age in AD mice
The hippocampus is the first and most profoundly affected brain region with respect to AD pathology [16] . The loss of neurons and synapses in the hippocampus and other regions can explain why some of the first symptoms of AD are related to defects in declarative memory [17] . We first investigated the expression of NDRG2, GFAP, and Aβ1-42 with age in the hippocampus of AD mice, hemizygous APP/PS1 double-transgenic mice. Immunofluorescence staining was first performed, and as shown in Fig. 1A , the expression of NDRG2 increased with age in the hippocampus of APP/PS1 mice. Immunoblotting analysis was also carried out using hippocampal tissues. Consistent with the results of immunofluorescence staining, the protein levels of NDRG2 were significantly enhanced in aged mice compared to young mice (Fig.   1B ). Similar protein expression patterns were also found for GFAP and Aβ1-42 ( Fig.   1A and 1B). In addition, in healthy mice, no changes in NDRG2 protein levels were observed in the hippocampus, and similar protein expression patterns were also found for GFAP and Aβ1-42 (Fig. 1C) . These data suggested that NDRG2 might participate in the pathologic development of AD.
NDRG2 knockout exacerbated memory impairment in mimic AD mice generated with Aβ oligomer injection
To further verify whether NDRG2 could participate in the pathology of AD, J o u r n a l P r e -p r o o f two-month-old Ndrg2 -/-mice or Ndrg2 +/+ mice were injected with amyloid β peptide through the lateral ventricle to mimic AD development ( Fig. 2A) . mice that received a saline injection (Fig. 2C) . AD is well known to be a progressive disease that involves memory impairment [19] . Therefore, to test whether the loss of NDRG2 could aggravate memory impairment in Aβ oligomer-injected mice, we administered a novel object recognition test. No difference was observed between
Ndrg2
-/-and Ndrg2 +/+ mice that received injection of Aβ oligomers or saline in the exploration time ratio between the two identical objects. Subsequently, in an intersession interval (ISI) of 1 h, 24 h or 48 h, we replaced one of the identical objects with a novel object and then allowed the mice to explore in the open field again to detect the effect of NDRG2 on short-term and long-term memory (Fig. 2D) . During the ISI 1 h experiment, we found that the recognition time for novel objects in both J o u r n a l P r e -p r o o f [18] . Together, these data suggest that NDRG2 is required for maintaining long-term memory in mimic AD mice generated with Aβ oligomer injection. (Fig. 3A) . The genotypes of the hybridized mice were identified ( Supplementary Fig. 1 ), and we then detected (Fig. 4B ).
NDRG2 deficiency worsened memory damage in APP/PS1 mice
J o u r n a l P r e -p r o o f
Taken together, these results suggest that NDRG2 deficiency were implicated an exacerbated memory impairment in AD mice.
NDRG2 deficiency increased astroglial activation in mimic AD mice
NDRG2 is mainly expressed in astrocytes but not in neurons in rodents [12] . NDRG2
is implicated in an astroglial activation-associated inflammation response in a cortical stab injury mouse model [20] . Thus, we wondered whether the astroglial response is involved in NDRG2 loss-mediated memory damage. The expression of GFAP is referred to as reactive astrogliosis or astroglial activation [21] . Despite Aβ oligomer injection-induced reactive astrogliosis in both Ndrg2 +/+ and Ndrg2 -/-mice, there was more fluorescent staining of GFAP in the hippocampus of Ndrg2 -/-mice than in Ndrg2 +/+ mice (Fig. 5A ). Immunoblotting analysis was also carried out to quantify astroglial activation in the hippocampus. The protein levels of GFAP were significantly increased in Ndrg2 -/-mice injected with Aβ oligomers compared with J o u r n a l P r e -p r o o f +/+ mice (Fig. 5B) . Therefore, these data indicate that Aβ oligomer stress can induce reactive astrogliosis and that NDRG2 deficiency enhances astroglial activation.
NDRG2 is required for the stabilization of the proteasome functional subunit
The ubiquitin-proteasome system (UPS), a major intracellular protein, is well known to be related to AD pathogenesis [22] . The proteasome complex is a major regulator and an essential proteolytic enzyme for the degradation of Aβ and tau proteins [23] .
PSMB5, PSMB6, and PSMB7 subunits belong to the 20S proteasomal subunit family and play important roles in protein degradation [24] [25] [26] [27] [28] [29] . We found that the levels of (Fig. 6) . Together, these results suggest that reduced PSMB6 expression may be involved in NDRG2
deficiency-mediated deteriorations in AD memory impairment. However, why and how NDRG2 deficiency leads to abnormal expression of PSMB6 need to be further investigated.
Discussion
In the present study, we found that the expression of NDRG2 increased with age in AD mice and that NDRG2 deficiency resulted in a deterioration in memory impairment of AD mice.
Memory loss is well known to be the defining presenting symptom in patients with AD [30] , and Aβ accumulation plays a leading role in the pathogenesis of AD [31] [32] [33] .
Interestingly, NDRG2 is an early-stage stress response gene in AD progression [14] .
A previous study reported that NDRG2 was upregulated in the brains of patients with AD [13] . Here, we found APP/PS1 mice showed an increase in the expression levels of NDRG2 with age, which is consistent with results from AD patients [13] . However, whether the increase in NDRG2 is associated with progressive disease or a protective response in AD remains unknown.
We previously reported that Ndrg2 -/-mice exhibited attention-deficit/hyperactivity disorder (ADHD)-like symptoms characterized by attention deficits, hyperactivity, impulsivity, and impaired memory [18] . Interstitial glutamate levels and excitatory transmission were markedly increased in the brains of Ndrg2 -/-mice due to reduced astroglial glutamate clearance, which may be associated the ADHD-like behaviors in
Ndrg2
-/-mice. Here, we found that two-month-old Ndrg2 -/-mice injected with Aβ oligomers had aggravated memory deficit compared with Ndrg2 -/-mice injected with saline. However, the hyperactivity in Ndrg2 -/-mice was significantly decreased after intracerebroventricular injection with Aβ oligomers. We hypothesized that accumulated Aβ oligomers in Ndrg2 -/-mice affect not only memory but also locomotor activity.
-/-APP/PS1 mice showed a significantly worse memory compared to
+/-APP/PS1 mice with ISI 24 h. We noticed that the novel object exploration time in Ndrg2 +/-APP/PS1 mice with ISI 24 h (ratio is around 0.6) was relatively higher compared with the APP/PS1 mice in previous reports (ratio is around 0.5) [34] .
We speculated this baseline value variation is owing to different experimental systems and mice lines, although both mice were control mice. In addition, there is a very low Our data suggest that NDRG2 deficiency could exacerbate long-term memory impairment in two AD mice models. We speculate that NDRG2 deficiency may affect the expression or function of AD-associated long-term memory proteins such as kinase M zeta [35, 36] and brain-derived neurotrophic factor [37, 38] , although this needs to be further studied.
Recent studies have revealed that a malfunction of the proteasome complex plays an important role in AD development [39] . Although the exact mechanism of the pathological process of AD is not fully clarified, the dysfunction of the protein degradation mechanisms has been proposed to play an important role in AD [40] . The ubiquitin-proteasome system (UPS) is essential for protein repair, turnover and degradation and is perturbed in AD [41] . The level of Aβ1-42 was significantly increased in Ndrg2 -/-mice injected with Aβ oligomers compared with Ndrg2 +/+ mice injected with Aβ oligomers, suggesting a problem in the Aβ1-42 protein degradation process. Therefore, we hypothesize that the loss of NDRG2 may affect the proteasome system, which is the major intracellular protein quality control system.
PSMB5, PSMB6 and PSMB7 subunits belong to the 20S proteasomal subunit family, which plays an important role in protein degradation and repair. Our data showed decreased expression of PSMB6 in NDRG2-deficient AD mice. PSMB6 is a member of the proteasome β-type family and participates in the formation of proteolytic centers of the proteasome machinery [42] .
NDRG2 has protective effects in both acute and chronic brain disorders such as ischemia and depression [43] [44] [45] . In the present study, we found that NDRG2
silencing induced Aβ accumulation and worsened memory impairment, which was contradictory to another report on the role of NDRG2 in AD [15] . In that study, human APP695 SK-N-SH cells were used in vitro to mimic AD, and NDRG2
silencing significantly reduced the levels of Aβ in these cultured cells. However, in our study, we found that Aβ expression levels in Ndrg2 J o u r n a l P r e -p r o o f
